OmniAb, Inc. (NASDAQ:OABI – Get Free Report) shares crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $4.82 and traded as low as $4.61. OmniAb shares last traded at $4.66, with a volume of 1,898,286 shares.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on OABI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of OmniAb in a research note on Wednesday. Leerink Partners lifted their target price on shares of OmniAb from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Wednesday, October 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of OmniAb in a report on Monday, August 17th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, OmniAb presently has an average rating of “Moderate Buy” and an average price target of $11.50.
Get Our Latest Research Report on OmniAb
OmniAb Stock Down 7.4%
The stock has a 50 day moving average of $4.82 and a 200 day moving average of $2.94. The firm has a market cap of $679.71 million, a price-to-earnings ratio of -13.71 and a beta of 0.60.
OmniAb (NASDAQ:OABI – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. OmniAb had a negative return on equity of 16.74% and a negative net margin of 108.11%. The company had revenue of $3.99 million during the quarter, compared to analysts’ expectations of $3.49 million. As a group, analysts predict that OmniAb, Inc. will post -0.34 EPS for the current fiscal year.
Institutional Investors Weigh In On OmniAb
A number of institutional investors have recently made changes to their positions in the stock. Whitefort Capital Management LP acquired a new position in OmniAb in the second quarter valued at $25,211,699. BlackRock Inc. bought a new position in shares of OmniAb in the second quarter valued at approximately $21,888,000. State Street Corp boosted its stake in OmniAb by 6.7% in the third quarter. State Street Corp now owns 2,277,008 shares of the company’s stock valued at $11,294,000 after acquiring an additional 143,459 shares during the last quarter. Rice Hall James & Associates LLC purchased a new stake in OmniAb in the 2nd quarter worth about $6,422,000. Finally, Goldman Sachs Group Inc. purchased a new position in OmniAb in the 3rd quarter valued at approximately $3,375,000. Institutional investors own 72.08% of the company’s stock.
OmniAb Company Profile
OmniAb, Inc. is a biotechnology company that develops antibody discovery technologies for use in creating therapeutic medicines. It works with pharmaceutical and biotechnology companies to identify and advance antibody candidates for potential drug development. Its platform includes genetically engineered animals that can produce antibodies with human characteristics, along with related discovery and screening technologies. These tools are designed to help partners find antibodies for a range of therapeutic targets and applications.
Featured Stories
- Five stocks we like better than OmniAb
- Growing Pains Versus Growth: Is BJ’s Wholesale Club a Buying Opportunity?
- Keysight Technologies: The Tollbooth on the Technology Superhighway
- Zscaler Got a Boost From Palo Alto, But Now It Has to Deliver.
- Bargain Hunting: Why Off-Price Retail Is Winning
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
